Immunotherapy is a promising treatment strategy for cancer that has recently shown
unprecedented survival benefits in selected patients. A number of immunomodulatory …

Immune checkpoint blockade has been a pivotal development in the management of
advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and …

Recent advances in our understanding of the dynamics of cellular cross-talk have
highlighted the significance of host-versus-tumor effect that can be harnessed with immune …

Background Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of
the response to anti-PD-L1/anti-programmed cell death 1 (PD-1) therapy in multiple cancers …

Background: The aim of this study was to reveal the clinicopathological and molecular
characteristics of microsatellite instability-high (MSI-H) colorectal cancers (CRCs) showing …

The introduction of immune checkpoint blockade (ICB) therapy has transformed the
management of advanced bladder cancer (BC). Despite its limitations, PD-L1 …

In patients with muscle invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC)
prior to radical cystectomy has improved survival but there is an urgent unmet need to …

Platinum-based chemotherapy is the standard of care in metastatic bladder cancer. With the
approval of various checkpoint inhibitors, immunotherapy has revolutionized the traditional …

Purpose The aim of this study was to elucidate the rates and prognostic roles of
programmed cell death ligand 1 (PD-L1) immunohistochemical (IHC) expression in various …

Background Despite recent studies, the effect of chemotherapy on programmed death-
ligand 1 (PD-L1) expression remains controversial. In this study, we investigated whether …